View Financial HealthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest Eventse-therapeutics 配当と自社株買い配当金 基準チェック /06e-therapeutics配当金を支払った記録がありません。主要情報n/a配当利回り-0.06%バイバック利回り総株主利回り-0.06%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • May 07e-therapeutics plc Presents New Data Supporting ETX-312 as a Differentiated and Disease-Modifying Near-Clinic Treatment for MASHe-therapeutics plc announced it will present new preclinical results on its GalOmic small-interfering RNA (siRNA) candidate ETX-312 for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) at the European Association for the Study of the Liver (EASL) Congress, 7th-10th May 2025. In the leading Gubra-Amylin NASH diet-induced obese (GAN-DIO) mouse model, ETX-312 demonstrated: Dramatic improvements in NAFLD Activity Score (NAS) when administered as monotherapy or in combination with a GLP-1/GIP receptor agonist or an FGF-21 analogue. All mice receiving combination therapy achieved 2-point reductions in NAS, with improvements of up to 5 points observed. Slowed fibrosis progression comparable to that achieved with GLP-1/G IP receptor agonist or FGF-21 analogue controls, supported by statistically significant reductions in hepatic collagen staining and in circulating biomarkers TIMP-1 and PIIINP. ETX-312 is currently in IND-enabling studies, and the Company remains on track to submit a regulatory submission by the end of 2025.お知らせ • Apr 11e-therapeutics plc Considers Switching Its Listing to New YorkShares of e-therapeutics plc fell 12% after the company said it is considering switching its listing to New York, a move that would deal a further blow to the London bourse following a spate of defections in recent months. The provider of digital technology for drug discovery also said April 10, 2024 that it raised GBP 28.9 million ($36.6 million) via a high-premium share subscription by its two largest shareholders. Shares at 0752 GMT were down 1.50 pence at 11.0 pence. They are currently down 25% over the past 12 months. e-Therapeutics is seeking shareholder approval to cancel its current listing on London's junior AIM, saying it doesn't believe it accurately reflects its value and is a hindrance to its plans given a significant reduction in liquidity and access to capital. It also said it believes a listing on U.S. Nasdaq will provide a higher valuation, but cautioned that there is no certainty the listing will be achievable in any given time frame. The London delisting plan has the support of shareholders owing 46.68% of its shares, it said. e-Therapeutics has called a general meeting for April 29 to seek approval to delist its shares, and if approved, expects cancellation to become effective from May 9.お知らせ • Apr 10e-therapeutics plc, Annual General Meeting, Apr 29, 2024e-therapeutics plc, Annual General Meeting, Apr 29, 2024, at 11:30 Coordinated Universal Time. Location: Unit 4B, Floor 4, 4 Kingdom Street, Paddington Central London United Kingdomお知らせ • Dec 27e-therapeutics Ordinary Shares to Cease to Trade on the OTCQX Best Market in the United Statese-therapeutics plc announced that, with effect from 31 December 2023, its ordinary shares ("Ordinary Shares") will cease to trade on the OTCQX Best Market in the United States ("OTCQX"). The Company's Ordinary Shares began trading on OTCQX on 24 September 2021, but there has been limited trading since that date. As such, the expenses associated with the Company's Ordinary Shares trading on OTCQX outweigh the benefits for e-therapeutics shareholders. The Ordinary Shares will continue to be admitted to trading on AIM as the Company's primary market.お知らせ • Oct 20e-therapeutics plc to Report First Half, 2024 Results on Oct 26, 2023e-therapeutics plc announced that they will report first half, 2024 results on Oct 26, 2023お知らせ • Sep 21E-Therapeutics plc Announces Senior Management Updatee-therapeutics plc announces that Michael Bretherton has stepped down from his role as interim CFO and will now focus on his role as a Non-Executive Director of the Company. Timothy Bretherton, Director of Finance and Operations, will assume the CFO role (non-board) with immediate effect. Timothy is an experienced finance leader having held multiple senior roles prior to joining e-therapeutics in May 2022. He has a strong practical background previously gained over 12 years in operational and finance roles including four years as a consultant at PwC and three years as an auditor at Mazars. He has a degree in Economics from the University of Leicester and is a member of the Institute of Chartered Accountants in England and Wales.お知らせ • May 11e-therapeutics plc, Annual General Meeting, Jul 18, 2023e-therapeutics plc, Annual General Meeting, Jul 18, 2023, at 11:30 Coordinated Universal Time. Location: 4 Kingdom Street Paddington, London W2 6BD London United Kingdom Agenda: To receive the accounts for the financial year ended 31 January 2023 together with the Directors' Report and the Auditor's Report for that period; to re-elect Ali Mortazavi as a Director of the Company, who has been a Director since 10 February 2020 and was last re-elected by shareholders in March 2020; to re-appoint Crowe U.K. LLP as the Auditor of the Company; to authorise the Directors to set the remuneration of the Auditor of the Company; and to consider other matters.決済の安定と成長配当データの取得安定した配当: ETXP.Fの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: ETXP.Fの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場e-therapeutics 配当利回り対市場ETXP.F 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (ETXP.F)n/a市場下位25% (US)1.4%市場トップ25% (US)4.3%業界平均 (Biotechs)2.4%アナリスト予想 (ETXP.F) (最長3年)n/a注目すべき配当: ETXP.Fは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: ETXP.Fは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: ETXP.Fの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: ETXP.Fが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/07/14 13:07終値2024/04/16 00:00収益2024/01/31年間収益2024/01/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋e-therapeutics plc 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • May 07e-therapeutics plc Presents New Data Supporting ETX-312 as a Differentiated and Disease-Modifying Near-Clinic Treatment for MASHe-therapeutics plc announced it will present new preclinical results on its GalOmic small-interfering RNA (siRNA) candidate ETX-312 for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) at the European Association for the Study of the Liver (EASL) Congress, 7th-10th May 2025. In the leading Gubra-Amylin NASH diet-induced obese (GAN-DIO) mouse model, ETX-312 demonstrated: Dramatic improvements in NAFLD Activity Score (NAS) when administered as monotherapy or in combination with a GLP-1/GIP receptor agonist or an FGF-21 analogue. All mice receiving combination therapy achieved 2-point reductions in NAS, with improvements of up to 5 points observed. Slowed fibrosis progression comparable to that achieved with GLP-1/G IP receptor agonist or FGF-21 analogue controls, supported by statistically significant reductions in hepatic collagen staining and in circulating biomarkers TIMP-1 and PIIINP. ETX-312 is currently in IND-enabling studies, and the Company remains on track to submit a regulatory submission by the end of 2025.
お知らせ • Apr 11e-therapeutics plc Considers Switching Its Listing to New YorkShares of e-therapeutics plc fell 12% after the company said it is considering switching its listing to New York, a move that would deal a further blow to the London bourse following a spate of defections in recent months. The provider of digital technology for drug discovery also said April 10, 2024 that it raised GBP 28.9 million ($36.6 million) via a high-premium share subscription by its two largest shareholders. Shares at 0752 GMT were down 1.50 pence at 11.0 pence. They are currently down 25% over the past 12 months. e-Therapeutics is seeking shareholder approval to cancel its current listing on London's junior AIM, saying it doesn't believe it accurately reflects its value and is a hindrance to its plans given a significant reduction in liquidity and access to capital. It also said it believes a listing on U.S. Nasdaq will provide a higher valuation, but cautioned that there is no certainty the listing will be achievable in any given time frame. The London delisting plan has the support of shareholders owing 46.68% of its shares, it said. e-Therapeutics has called a general meeting for April 29 to seek approval to delist its shares, and if approved, expects cancellation to become effective from May 9.
お知らせ • Apr 10e-therapeutics plc, Annual General Meeting, Apr 29, 2024e-therapeutics plc, Annual General Meeting, Apr 29, 2024, at 11:30 Coordinated Universal Time. Location: Unit 4B, Floor 4, 4 Kingdom Street, Paddington Central London United Kingdom
お知らせ • Dec 27e-therapeutics Ordinary Shares to Cease to Trade on the OTCQX Best Market in the United Statese-therapeutics plc announced that, with effect from 31 December 2023, its ordinary shares ("Ordinary Shares") will cease to trade on the OTCQX Best Market in the United States ("OTCQX"). The Company's Ordinary Shares began trading on OTCQX on 24 September 2021, but there has been limited trading since that date. As such, the expenses associated with the Company's Ordinary Shares trading on OTCQX outweigh the benefits for e-therapeutics shareholders. The Ordinary Shares will continue to be admitted to trading on AIM as the Company's primary market.
お知らせ • Oct 20e-therapeutics plc to Report First Half, 2024 Results on Oct 26, 2023e-therapeutics plc announced that they will report first half, 2024 results on Oct 26, 2023
お知らせ • Sep 21E-Therapeutics plc Announces Senior Management Updatee-therapeutics plc announces that Michael Bretherton has stepped down from his role as interim CFO and will now focus on his role as a Non-Executive Director of the Company. Timothy Bretherton, Director of Finance and Operations, will assume the CFO role (non-board) with immediate effect. Timothy is an experienced finance leader having held multiple senior roles prior to joining e-therapeutics in May 2022. He has a strong practical background previously gained over 12 years in operational and finance roles including four years as a consultant at PwC and three years as an auditor at Mazars. He has a degree in Economics from the University of Leicester and is a member of the Institute of Chartered Accountants in England and Wales.
お知らせ • May 11e-therapeutics plc, Annual General Meeting, Jul 18, 2023e-therapeutics plc, Annual General Meeting, Jul 18, 2023, at 11:30 Coordinated Universal Time. Location: 4 Kingdom Street Paddington, London W2 6BD London United Kingdom Agenda: To receive the accounts for the financial year ended 31 January 2023 together with the Directors' Report and the Auditor's Report for that period; to re-elect Ali Mortazavi as a Director of the Company, who has been a Director since 10 February 2020 and was last re-elected by shareholders in March 2020; to re-appoint Crowe U.K. LLP as the Auditor of the Company; to authorise the Directors to set the remuneration of the Auditor of the Company; and to consider other matters.